CD33 and acute myeloid leukemia: After initially accelerated FDA approval in 2000 for the treatment of CD33-positive-AML aged ≥ 60 years in first relapse, GO was withdrawn from the market in June 2010 due to negative results of the phase 3 Southwest Oncology Group (SWOG) study S0106 showing significantly higher induction mortality without improving CR or relapse-free survival [33, 34].